Pharma/Biotech Update: SPARK & Pfizer Reach Deal
December 10, 2014; Posted by: WeBleed staff
Spark enters into partnership with Pfizer for hemophilia B treatments.
In a press release posted by Market Watch, Spark Therapeutics is now in collaborations with Pfizer Inc. for the development of SPK-FIX. This is a program that is advancing the association in gene therapy for hemophilia B with the bio-engineered adeno-association virus (AAV). Both Spark and Pfizer will work together with the hope of bringing this development to patients with hemophilia B.
“We believe Pfizer is the ideal partner for our hemophilia B program. Pfizer is a leader in hemophilia, developing the first recombinant Factor IX product,” said Dr. Katherine High, a hematologist and co-founder, president and chief scientific officer of Spark. Dr. High, who pioneered the development of AAV-mediated gene therapy for hemophilia, noted, “Pfizer’s longtime experience in hemophilia, including strong relationships with physicians, patients and payors, as well as clinical, regulatory and commercial capabilities, will complement our team’s deep knowledge of AAV-mediated gene transfer for the disease. We look forward to working with Pfizer with the goal of making gene therapy for hemophilia B a reality for patients.”
The agreement between both organizations allows Spark to receive $20 million with the possibility of an additional $260 million if the studies continue their success. Pfizer will gain responsibility of Spark’s SPK-FIX if it makes past the Phase 1 and 2 studies.
Interesting information concerning hemophilia B that hopes to continue to advance treatment of the bleeding disorder.
Photo Credit – Spark/Pfizer
webleed.org – your source for bleeding news!
